Spatially informed gene signatures for response to immunotherapy in melanoma
- PMID: 38837895
- DOI: 10.1158/1078-0432.CCR-23-3932
Spatially informed gene signatures for response to immunotherapy in melanoma
Abstract
Purpose: We aim to improve the prediction of response or resistance to immunotherapies in melanoma patients. This goal is based on the hypothesis that current gene signatures predicting immunotherapy outcomes show only modest accuracy due to the lack of spatial information about cellular functions and molecular processes within tumors and their microenvironment.
Experimental design: We collected gene expression data spatially from three cellular compartments defined by CD68+macrophages, CD45+leukocytes and S100B+tumor cells in 55-immunotherapy-treated melanoma specimens using Digital Spatial Profiling-Whole Transcriptome Atlas (DSP-WTA). We developed a computational pipeline to discover compartment-specific gene signatures and determine if adding spatial information can improve patient stratification.
Results: We achieved robust performance of compartment-specific signatures in predicting the outcome to ICI in the discovery cohort. Of the three signatures, S100B signature showed the best performance in the validation cohort (N=45). We also compared our compartment-specific signatures with published bulk signatures and found the S100B tumor spatial signature outperformed previous signatures. Within the 8-gene S100B signature, 5 genes (PSMB8, TAX1BP3, NOTCH3, LCP2, NQO1) with positive coefficients predict the response and 3 genes (KMT2C, OVCA2, MGRN1) with negative coefficients predict the resistance to treatment.
Conclusion: We conclude that the spatially defined compartment signatures utilize tumor and TME-specific information, leading to more accurate prediction of treatment outcome, and thus merit prospective clinical assessment.
Similar articles
-
Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.Oncoimmunology. 2023 Sep 27;12(1):2260618. doi: 10.1080/2162402X.2023.2260618. eCollection 2023. Oncoimmunology. 2023. PMID: 37781235 Free PMC article.
-
High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC).J Immunother Cancer. 2024 Jun 10;12(6):e009039. doi: 10.1136/jitc-2024-009039. J Immunother Cancer. 2024. PMID: 38857914 Free PMC article.
-
High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.Clin Cancer Res. 2019 Sep 15;25(18):5503-5512. doi: 10.1158/1078-0432.CCR-19-0104. Epub 2019 Jun 12. Clin Cancer Res. 2019. PMID: 31189645 Free PMC article.
-
Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response.Arch Dermatol Res. 2024 May 25;316(6):262. doi: 10.1007/s00403-024-03080-3. Arch Dermatol Res. 2024. PMID: 38795156
-
Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.Genome Med. 2022 Apr 29;14(1):45. doi: 10.1186/s13073-022-01050-w. Genome Med. 2022. PMID: 35488273 Free PMC article.
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous